ArticleScientific reports2016
Bithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virus.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Development of a Graphene Oxide-Based Aptamer Nanoarray for Improved Neutralization and Protection Effects Against Ricin.Pharmaceutics · 2024Article
- Bithionol eliminates acute myeloid leukaemia stem-like cells by suppressing NF-κB signalling and inducing oxidative stress, leading to apoptosis and ferroptosis.Cell death discovery · 2024Article
- The potential target of bithionol against Staphylococcus aureus: design, synthesis and application of biotinylated probes Bio-A2.The Journal of antibiotics · 2023Article
- Alternative Targets for Modulators of Mitochondrial Potassium Channels.Molecules (Basel, Switzerland) · 2022Review
- Host Molecules Regulating Neural Invasion of Zika Virus and Drug Repurposing Strategy.Frontiers in microbiology · 2022Review
- An Electrochemical Approach to Follow and Evaluate the Kinetic Catalysis of Ricin on hsDNA.Life (Basel, Switzerland) · 2021Article
- Zika virus pathogenesis and current therapeutic advances.Pathogens and global health · 2021Review
- Identification of Bithionol, Dichlorophen, and Miconazole as Antibacterial Agents againstACS omega · 2020Article
- Repurposing Clinically Approved Drugs for the Treatment ofACS omega · 2020Article
- Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Cholera: an overview with reference to the Yemen epidemic.Frontiers of medicine · 2019Review
- Review
- ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments.Scientific reports · 2017Article
- Review
- Therapeutic Approaches for Zika Virus Infection of the Nervous System.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Advances in Developing Therapies to Combat Zika Virus: Current Knowledge and Future Perspectives.Frontiers in microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Funding
Abstract
Diverse pathogenic agents often utilize overlapping host networks, and hub proteins within these networks represent attractive targets for broad-spectrum drugs. Using bacterial toxins, we describe a new approach for discovering broad-spectrum therapies capable of inhibiting host proteins that mediate multiple pathogenic pathways. This approach can be widely used, as it combines genetic-based target identification with cell survival-based and protein function-based multiplex drug screens, and concurrently discovers therapeutic compounds and their protein targets. Using B-lymphoblastoid cells derived from the HapMap Project cohort of persons of African, European, and Asian ancestry we identified host caspases as hub proteins that mediate the lethality of multiple pathogenic agents. We discovered that an approved drug, Bithionol, inhibits host caspases and also reduces the detrimental effects of anthrax lethal toxin, diphtheria toxin, cholera toxin, Pseudomonas aeruginosa exotoxin A, Botulinum neurotoxin, ricin, and Zika virus. Our study reveals the practicality of identifying host proteins that mediate multiple disease pathways and discovering broad-spectrum therapies that target these hub proteins.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.